ArticleEuropean radiology2026
Malignant pleural mesothelioma classification and survival prediction with CT imaging using ResNet.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Recent advances in artificial intelligence across interventional pulmonology: a narrative review.Journal of thoracic disease · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
objectivesThis study aims to achieve accurate differentiation of malignant pleural mesothelioma (MPM) from metastatic pleural disease (MPD) and to predict the overall survival of MPM. MATERIALS AND
methodsThis IRB-approved retrospective study included 385 subjects in total (85 patients with malignant mesothelioma and 290 with MPD secondary to lung adenocarcinoma). A ResNet-3D-18 model was trained on annotated pretreatment CT scans to distinguish MPM from MPD. Using chronological segregation, the training cohort included 70 histologically confirmed mesothelioma and 258 MPD cases, with an independent test cohort of 15 MPM and 32 MPD cases for validation. A multivariate logistic regression model served as the clinical benchmark for comparison. Deep learning features extracted from the trained ResNet model were then assessed for their prognostic utility in MPM patients using a random forest classifier. Model performance was evaluated at both lesion- and patient-levels, with metrics including the area under the ROC curve (AUC), accuracy, sensitivity, specificity, positive predictive value, and negative predictive value.
resultsThe ResNet-3D-18 model demonstrated excellent discriminative performance in differentiating MPM from MPD, with mean AUCs of 0.972 (95% CI 0.947-0.990) and 0.840 (95% CI 0.757-0.929) in the training and independent test cohorts. Compared to the clinical model, the deep learning approach showed higher sensitivity (0.867 vs. 0.533) in the independent test dataset. For overall survival prediction in MPM patients, the random forest classifier achieved an AUC of 0.829 (95% CI 0.663-0.943) in 5-fold cross-validation.
conclusionsResNet-3D-18 classification model has excellent abilities in differentiating MPM from MPD, and morphological distinctions between MPM and MPD also contain prognostic information. KEY POINTS: Question The rising global incidence of malignant pleural mesothelioma contrasts with persistent diagnostic challenges. Findings Deep learning-derived discriminative features simultaneously contain prognostic information. Clinical relevance This study bridges the gap between radiological findings and clinical decision-making in MPM, offering a reproducible tool for early diagnosis and personalized prognosis prediction based on CT imaging alone.
Indexed as
Identifiers
41168494What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.